IPO

About Occlutech

Occlutech is a leading specialist provider of minimally invasive cardiac devices, with a mission to improve the quality of life for people with heart conditions. The vision is to become a global leading specialist provider in cardiac devices, addressing congenital heart defects, stroke prevention and heart failure. 

Since 2003, Occlutech has developed, manufactured, and commercialized occluders and interatrial shunt products. Occlutech has a broad and proven portfolio, based on proprietary technology, and over 200 patents with more than 134,000 products sold.

Occlutech markets and sells its structural heart and interatrial shunt products to hospitals and clinics in approximately 85 countries through its direct sales organization and international network of distribution partners.

Occlutech has around 250 employees and maintains manufacturing and R&D facilities in Jena, Germany and Istanbul, Turkey, with a global supply and customer support hub located in Helsingborg, Sweden.

Prospectus and application forms

Occlutech’s prospectus (in Swedish with an English translation), which contains full terms and instructions for the Offering is attached in this section. During the application period, the prospectus will also be available on Carnegie’s website (www.carnegie.se), Nordnet’s website (www.nordnet.se) and Avanza’s website (www.avanza.se), and, within a couple of days, the Swedish Financial Supervisory Authority’s website (https://fi.se/en/our-registers/prospektregistret/). Applications from the public can be made through Avanza and Nordnet in accordance with the terms set out in the prospectus. 

Preliminary timetable

Application period: 17 September - 28 September 2021
First day of trading on Nasdaq First North Premier Growth Market: 29 September 2021
Settlement day: 1 October 2021

Advisers

Carnegie acts as Sole Global Coordinator and Joint Bookrunner and Bryan, Garnier & Co. acts as Joint Bookrunner. Baker McKenzie is the legal adviser to Occlutech as to Swedish, Swiss and US law. Roschier Advokatbyrå is the legal advisor to Carnegie and Bryan, Garnier & Co. FNCA Sweden AB is the Certified Adviser to the Company.

Press Releases

Subscribe

Contacts

Sabine Bois

Sabine Bois

Lars Wadell

Lars Wadell

General Information

+46 704 33 65 25